Skip to main content
. 2019 Sep 14;19:924. doi: 10.1186/s12885-019-6103-5

Fig. 7.

Fig. 7

Model for Smac mimetic anti-osteosarcoma efficacy. Smac mimetic treatment induces osteosarcoma cells to activate TNFR1-mediated cell death pathways in response to TNFα produced by intratumoral immune cells